GSK says efficacy of its shingles vaccine remains high after years
(Reuters) - British drugmaker GSK said on Wednesday long-term data showed that its blockbuster shingles vaccine, Shingrix, had 79.7% efficacy in participants aged 50 years and above, six to 11 years after vaccination.
The vaccine's efficacy remained high at 82% at year 11 after initial vaccination, GSK said, citing data from a long-term follow-up, late-stage trial that tracked participants for up to about 11 years after they were first vaccinated with Shingrix.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Savio D'Souza)
